HHLA2 and hepatocellular carcinoma: Furthermore, to assess HHLA2’s impact in vivo, we utilized an established and rapid hydrodynamic tail vein injection (HDTVi) model in which oncogenic N-RasV12/myr-AKT1 activates key signaling pathways relevant to HCC and c-Met activity [28, 29].